Clinical trials: Breast Cancer Risk
Breast Cancer
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
The purpose of this study is to learn whether daily use of Duavee® is accepted and tolerated by peri- and post-menopausal women at moderate risk for development of breast cancer.
- Trial name
- NCT02729701
- Testing
- Duavee
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Kansas Medical Center
Breast Neoplasms
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2…
- Trial name
- EMBER-4 (NCT05514054)
- Testing
- Imlunestrant, Tamoxifen, Anastrozole
- Where
- 672 sites in United States, Argentina and 29 more
- Volunteers
- 8,000 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Mammographic Density
The Malaysian Soy and Mammographic Density Study
Globally, breast cancer is the most common cancer and the main cause of deaths due to cancer. This is attributed to changes in reproductive habits as well as an increasingly sedentary lifestyle, with low physical activity and…
- Trial name
- MiSo (NCT03686098)
- Testing
- Dietary soy, Soy Supplement
- Where
- Malaysia
- Volunteers
- 282 people, healthy volunteers welcome
- Sponsor
- Cancer Research Malaysia
Breast Carcinoma
Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
This clinical trial studies the effects of dietary white button mushroom on inflammation (the body's process of fighting against harmful things) and immune cells (white blood cells) in postmenopausal women with both high body…
- Trial name
- NCT04913064
- Testing
- Questionnaire Administration, White Button Mushroom Extract
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Hereditary Breast and Ovarian Cancer Syndrome
Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
Young female counselees (18-40 years) belonging to HBOC families with a known mutation on BRCA-genes or not, receive a lot of information regarding their cancer risk. Information sources are numerous and sometimes contradictory.
- Trial name
- NCT02705924
- Testing
- psychoeducation
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Jean Perrin
Breast Cancer
Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
This protocol will evaluate the feasibility and toxicity of dose-dense docetaxel followed by doxorubicin and cyclophosphamide with support given as adjuvant or neoadjuvant treatment of women with node positive and high risk…
- Trial name
- NCT00193115
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 32 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Adenocarcinoma of Breast
Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer
This study was a transnational pooled analysis of biological material from patients with resected high risk breast cancer who had received adjuvant chemotherapy with epirubicin and cyclophosphamide followed by weekly docetaxel or…
- Trial name
- NCT04829890
- Volunteers
- 89 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
Tailored Screening for Breast Cancer in Premenopausal Women
The Tailored Breast Screening Trial (TBST) is a population-based, non-inferiority randomised trial aimed at evaluating the impact of tailored screening strategies addressed to premenopausal women, by using breast density as…
- Trial name
- TBST (NCT02619123)
- Testing
- Tailored screening according to breast density, Annual invitation to mammography
- Where
- 5 sites in Italy
- Volunteers
- 33,200 people, healthy volunteers welcome
- Sponsor
- Cancer Prevention and Research Institute, Italy
Observational Study
The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study
The aim of the current study is to investigate the association between hormonal intake, occupational and demographic factors, and the risk of breast cancer (BC) among Egyptian females.
- Trial name
- NCT05135013
- Testing
- Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- NewGiza University
Breast Cancer Risk Factors
Night-shift Work and Breast Cancer
Scientific evidence established about the effects of night work on health both in the short term (insomnia, excessive sleepiness, difficulty concentrating or lack of energy) and in the long term (moderately high risk of…
- Trial name
- BC-NSW-02/2023 (NCT06786949)
- Testing
- Questionnaire, Blood samples for biomarker measurement
- Where
- 2 sites in Italy
- Volunteers
- 6,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Gastrointestinal Mucositis (Defined as Mucositis Involving the Mouth, Esophagus, or Small Intestine)
TRIAD Burden of Illness Mucositis Study
Observational (non-drug) study to look at the risks and burden of mucositis (sores) involving the mouth, throat and intestines in patients receiving chemotherapy and radiation therapy treatment for various cancer types.
- Trial name
- NCT00336609
- Where
- United States
- Volunteers
- 1,600 people
- Sponsor
- TRIAD Burden of Illness
Breast Cancer
Tamoxifen-MRI Study
The project is a double blind, randomized, placebo-controlled phase II chemoprevention trial. Study participants will be randomly assigned to receive either tamoxifen or placebo for one year.
- Trial name
- NCT00295100
- Testing
- Tamoxifen
- Where
- 7 sites in United States, Italy
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Breast Cancer
Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study
The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast…
- Trial name
- GENRE2 (NCT04474834)
- Testing
- Polygenic Risk Score
- Where
- 5 sites in United States
- Volunteers
- 737 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Social Determinants of Health, Breast Cancer
Social Risk Factors and Discrimination in Cancer Survivorship
The objective of the proposed study is to scale social risk factor screening and referral for cancer survivors and to solidify information exchange between clinical and community settings in order to improve survivor health and…
- Conditions
- Social Determinants of Health, Breast Cancer, Prostate Cancer, Health Equity
- Trial name
- NCT05301114
- Testing
- Community Health Worker support
- Where
- United States
- Volunteers
- 506 people
- Sponsor
- Medstar Health Research Institute
Breast Cancer, Upper Extremity Deep Vein Thrombosis, Secondary
Determination of Predictive Value of Echography Doppler Abnormalities
In order to avoid to use a traumatic and iatrogenic examen (phlebography), the purpose of the study is to validate echography doppler in the diagnosis of asymptomatic related catheter related thrombosis.
- Trial name
- CAVECCAS (NCT00714909)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Low-Risk, Early Stage Breast Cancer
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy.
- Trial name
- NCT07629206
- Testing
- Cryoablation
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- IceCure Medical Ltd.
Menopause, Postmenopausal Bone Loss
Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy
Women undergoing surgical menopause often experience marked menopausal side effects but are reluctant to use estrogen or other female hormones to ease the transition to menopause because of worries that the hormones may increase…
- Conditions
- Menopause, Postmenopausal Bone Loss, Breast Cancer
- Trial name
- NCT00165204
- Testing
- Tibolone
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Lumpectomy
Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast Cancer
The standard treatment for localized breast cancer is based on conservative surgery (when possible) followed by radiation therapy (RT) delivered to the whole breast.
- Trial name
- SHARE (NCT01247233)
- Testing
- Whole Breast Irradiation + Boost or Hypofractionated irradiation, Accelerated partial breast irradiation
- Where
- 34 sites in France
- Volunteers
- 1,006 people
- Sponsor
- UNICANCER
Breast Cancer
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
- Trial name
- BETH (NCT00625898)
- Testing
- Docetaxel, Trastuzumab, Carboplatin
- Where
- 649 sites in United States, Argentina and 38 more
- Volunteers
- 3,509 people
- Sponsor
- NSABP Foundation Inc